SPRC SciSparc Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1611746 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-54.6%
TTM net income YoY-22.7%
TTM EPS YoY-91.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin38.7%
Operating margin-560.2%
Net margin-481.2%
FCF margin—
EBITDA margin-523.3%
Returns
ROE-79.7%
ROA-58.4%
ROIC (approx.)-95.1%
Asset turnover0.12x
Leverage & solvency
Liabilities / assets13.6%
Debt / equity0.00x
Current ratio5.36x
Interest coverage-20.73x
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-11.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.31M | $2.88M |
| Cost of revenue | $800,000 | $683,000 |
| Gross profit | $506,000 | $2.20M |
| R&D expense | $1.71M | $1.64M |
| SG&A expense | $4.53M | $3.84M |
| Operating income | -$7.32M | -$6.82M |
| Interest expense | $353,000 | $1.05M |
| Pretax income | -$7.49M | -$5.86M |
| Income tax | -$14,000 | $22,000 |
| Net income | -$6.28M | -$5.12M |
| EBITDA | -$6.83M | -$6.28M |
| EPS (basic) | 1.28 | 14.43 |
| EPS (diluted) | 1.28 | 14.43 |
| Weighted avg. shares (diluted) | 5.82M | 407,681 |
| Banking | ||
| Net interest income | -$259,000 | -$1.16M |
| Balance sheet | ||
| Cash & equivalents | $1.54M | $2.08M |
| Receivables | $10,000 | $22,000 |
| Inventory | $113,000 | $742,000 |
| Current assets | $7.50M | $6.45M |
| PP&E, netmay include right-of-use assets (IFRS) | $59,000 | $108,000 |
| Intangibles | $1.48M | $3.19M |
| Total assets | $10.35M | $11.18M |
| Current liabilities | $1.40M | $1.57M |
| Total liabilities | $1.41M | $1.59M |
| Shareholders' equity | $8.15M | $7.61M |
| Shares outstanding | 515,640 | 33,652 |
| Cash flow statement | ||
| Operating cash flow | -$5.10M | -$5.89M |
| Investing cash flow | -$1.62M | -$4.09M |
| Financing cash flow | $6.19M | $8.48M |
| Depreciation & amortization | $482,000 | $538,000 |
| Stock-based compensation | $569,000 | $196,000 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.